How much did BRAIN Biotech achieve in EBIT for the current year?
In the current year, BRAIN Biotech has achieved an EBIT of 545,400 EUR.
BRAIN Biotech EBIT 2024
BRAIN Biotech EBIT
545,400 EUR
Ticker
BNN.DE
ISIN
DE0005203947
WKN
520394
In 2024, BRAIN Biotech's EBIT was 545,400 EUR, a -115.94% increase from the -3.42 M EUR EBIT recorded in the previous year.
The BRAIN Biotech EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2029e | - |
| 2028e | 18.7 |
| 2027e | 13.15 |
| 2026e | 12.52 |
| 2025e | 6.44 |
| 2024e | 0.55 |
| 2023 | -3.42 |
| 2022 | -5.94 |
| 2021 | -7.06 |
| 2020 | -6.84 |
| 2019 | -4.82 |
| 2018 | -7.96 |
| 2017 | -8.17 |
| 2016 | -11.68 |
| 2015 | -5.13 |
| 2014 | -4.86 |
| 2013 | -4.39 |
| 2012 | -5.68 |
BRAIN Biotech Revenue, EBIT, Net Income DE0005203947 · 520394
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into BRAIN Biotech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BRAIN Biotech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BRAIN Biotech’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of BRAIN Biotech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into BRAIN Biotech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing BRAIN Biotech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BRAIN Biotech’s growth potential.
BRAIN Biotech Revenue, Profit, and EBIT History
| Date | BRAIN Biotech Revenue | BRAIN Biotech EBIT | BRAIN Biotech Net Income |
|---|---|---|---|
| 2029e | 98.15 M undefined | 0 undefined | 0 undefined |
| 2028e | 103.29 M undefined | 18.7 M undefined | 22.42 M undefined |
| 2027e | 91.08 M undefined | 13.15 M undefined | 15.2 M undefined |
| 2026e | 80.02 M undefined | 12.52 M undefined | 1.84 M undefined |
| 2025e | 71.55 M undefined | 6.44 M undefined | 1.02 M undefined |
| 2024e | 62.86 M undefined | 545,400 undefined | -5.22 M undefined |
| 2023 | 56.23 M undefined | -3.42 M undefined | -8.28 M undefined |
| 2022 | 50.3 M undefined | -5.94 M undefined | -6.59 M undefined |
| 2021 | 39.22 M undefined | -7.06 M undefined | -4.97 M undefined |
| 2020 | 39.06 M undefined | -6.84 M undefined | -9.68 M undefined |
| 2019 | 40.05 M undefined | -4.82 M undefined | -11.1 M undefined |
| 2018 | 29.05 M undefined | -7.96 M undefined | -7.92 M undefined |
| 2017 | 26.42 M undefined | -8.17 M undefined | -9.61 M undefined |
| 2016 | 25.04 M undefined | -11.68 M undefined | -14.69 M undefined |
| 2015 | 23.92 M undefined | -5.13 M undefined | -5.71 M undefined |
| 2014 | 12.99 M undefined | -4.86 M undefined | -5.3 M undefined |
| 2013 | 9.49 M undefined | -4.39 M undefined | -4.1 M undefined |
| 2012 | 7.27 M undefined | -5.68 M undefined | -5.54 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 7.27 M EUR | -5.68 M EUR | -5.54 M EUR |
| 2013 | 9.49 M EUR | -4.39 M EUR | -4.1 M EUR |
| 2014 | 12.99 M EUR | -4.86 M EUR | -5.3 M EUR |
| 2015 | 23.92 M EUR | -5.13 M EUR | -5.71 M EUR |
| 2016 | 25.04 M EUR | -11.68 M EUR | -14.69 M EUR |
| 2017 | 26.42 M EUR | -8.17 M EUR | -9.61 M EUR |
| 2018 | 29.05 M EUR | -7.96 M EUR | -7.92 M EUR |
| 2019 | 40.05 M EUR | -4.82 M EUR | -11.1 M EUR |
| 2020 | 39.06 M EUR | -6.84 M EUR | -9.68 M EUR |
| 2021 | 39.22 M EUR | -7.06 M EUR | -4.97 M EUR |
| 2022 | 50.3 M EUR | -5.94 M EUR | -6.59 M EUR |
| 2023 | 56.23 M EUR | -3.42 M EUR | -8.28 M EUR |
| 2024e | 62.86 M EUR | 545,400 EUR | -5.22 M EUR |
| 2025e | 71.55 M EUR | 6.44 M EUR | 1.02 M EUR |
| 2026e | 80.02 M EUR | 12.52 M EUR | 1.84 M EUR |
| 2027e | 91.08 M EUR | 13.15 M EUR | 15.2 M EUR |
| 2028e | 103.29 M EUR | 18.7 M EUR | 22.42 M EUR |
| 2029e | 98.15 M EUR | 0 EUR | 0 EUR |
BRAIN Biotech stock margins DE0005203947 · 520394
The BRAIN Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BRAIN Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BRAIN Biotech.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the BRAIN Biotech's sales revenue. A higher gross margin percentage indicates that the BRAIN Biotech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the BRAIN Biotech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the BRAIN Biotech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BRAIN Biotech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BRAIN Biotech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BRAIN Biotech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
BRAIN Biotech Margin History
| BRAIN Biotech Gross margin | BRAIN Biotech Profit margin | BRAIN Biotech EBIT margin | BRAIN Biotech Profit margin |
|---|---|---|---|
| 2029e | 55.16 % | 0 % | 0 % |
| 2028e | 55.16 % | 18.11 % | 21.71 % |
| 2027e | 55.16 % | 14.44 % | 16.69 % |
| 2026e | 55.16 % | 15.65 % | 2.3 % |
| 2025e | 55.16 % | 9 % | 1.42 % |
| 2024e | 55.16 % | 0.87 % | -8.31 % |
| 2023 | 55.16 % | -6.09 % | -14.72 % |
| 2022 | 56.13 % | -11.81 % | -13.1 % |
| 2021 | 57.12 % | -18 % | -12.68 % |
| 2020 | 56.42 % | -17.5 % | -24.79 % |
| 2019 | 56.44 % | -12.03 % | -27.72 % |
| 2018 | 52.98 % | -27.41 % | -27.25 % |
| 2017 | 57 % | -30.93 % | -36.37 % |
| 2016 | 54.39 % | -46.63 % | -58.67 % |
| 2015 | 54.07 % | -21.45 % | -23.89 % |
| 2014 | 63.13 % | -37.41 % | -40.8 % |
| 2013 | 56.59 % | -46.26 % | -43.2 % |
| 2012 | 46.49 % | -78.13 % | -76.2 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 46.49 % | -78.13 % | -76.2 % |
| 2013 | 56.59 % | -46.26 % | -43.2 % |
| 2014 | 63.13 % | -37.41 % | -40.8 % |
| 2015 | 54.07 % | -21.45 % | -23.89 % |
| 2016 | 54.39 % | -46.63 % | -58.67 % |
| 2017 | 57 % | -30.93 % | -36.37 % |
| 2018 | 52.98 % | -27.41 % | -27.25 % |
| 2019 | 56.44 % | -12.03 % | -27.72 % |
| 2020 | 56.42 % | -17.5 % | -24.79 % |
| 2021 | 57.12 % | -18 % | -12.68 % |
| 2022 | 56.13 % | -11.81 % | -13.1 % |
| 2023 | 55.16 % | -6.09 % | -14.72 % |
| 2024e | 55.16 % | 0.87 % | -8.31 % |
| 2025e | 55.16 % | 9 % | 1.42 % |
| 2026e | 55.16 % | 15.65 % | 2.3 % |
| 2027e | 55.16 % | 14.44 % | 16.69 % |
| 2028e | 55.16 % | 18.11 % | 21.71 % |
| 2029e | 55.16 % | 0 % | 0 % |
BRAIN Biotech Aktienanalyse
What does BRAIN Biotech do?
The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide. The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs. BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas: 1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol. 2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries. 3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion. BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production. An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency. Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production. In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing BRAIN Biotech's EBIT
BRAIN Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of BRAIN Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
BRAIN Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in BRAIN Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about BRAIN Biotech Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company BRAIN Biotech.
How has the EBIT of BRAIN Biotech developed in recent years?
The EBIT of BRAIN Biotech has increased by -115.938% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company BRAIN Biotech?
The EBIT of BRAIN Biotech is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does BRAIN Biotech pay?
Over the past 12 months, BRAIN Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BRAIN Biotech is expected to pay a dividend of 0 EUR.
What is the dividend yield of BRAIN Biotech?
The current dividend yield of BRAIN Biotech is .
When does BRAIN Biotech pay dividends?
BRAIN Biotech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BRAIN Biotech?
BRAIN Biotech paid dividends every year for the past 0 years.
What is the dividend of BRAIN Biotech?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is BRAIN Biotech located?
BRAIN Biotech is assigned to the 'Commodities' sector.
Wann musste ich die Aktien von BRAIN Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BRAIN Biotech from 6/28/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.
When did BRAIN Biotech pay the last dividend?
The last dividend was paid out on 6/28/2024.
What was the dividend of BRAIN Biotech in the year 2023?
In the year 2023, BRAIN Biotech distributed 0 EUR as dividends.
In which currency does BRAIN Biotech pay out the dividend?
The dividends of BRAIN Biotech are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BRAIN Biotech stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von BRAIN Biotech
Our stock analysis for BRAIN Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BRAIN Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- BRAIN Biotech Revenue
- BRAIN Biotech Net Income
- BRAIN Biotech P/E
- BRAIN Biotech P/S
- BRAIN Biotech EBIT
- BRAIN Biotech Dividend
- BRAIN Biotech Stocks
- BRAIN Biotech Market capitalization
- BRAIN Biotech Debt
- BRAIN Biotech Liabilities
- BRAIN Biotech Equity
- BRAIN Biotech AAQS
- BRAIN Biotech Employees
- BRAIN Biotech ROE
- BRAIN Biotech ROA
- BRAIN Biotech ROCE
